U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Pharmcore Inc. dba Hallandale Pharmacy - 605569 - 05/03/2022
  1. Warning Letters

CLOSEOUT LETTER

Pharmcore Inc. dba Hallandale Pharmacy MARCS-CMS 605569 —

Delivery Method:
Via Email
Product:
Drugs
Recipient:
Recipient Name
David G. Rabbani
Recipient Title
Owner and President
Pharmcore Inc. dba Hallandale Pharmacy

2666 SW 36th St
Fort Lauderdale, FL 33312-5005
United States

drabbani@hallandalerx.com
Issuing Office:
Office of Pharmaceutical Quality Operations, Division II

United States

Dear Mr. Rabbani :

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Case #605569), issued on March 11, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Caroline Le, PharmD.
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

cc:
VIA E-MAIL
Ms. Leilani Bellieni, QA Director
Pharmcore, Inc. dba Hallandale Pharmacy
2666 Southwest 36th Street
Fort Lauderdale, Florida 33312
leilani@hallandalerx.com

Back to Top